http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
선행 제왕절개술 후의 질식 분만 - 10 년간의 연구 -
나영정(Young Jeong Na),구미경(Mi Kyung Koo),박문일(Moon Il Park),김경태(Kyung Tai Kim),정성로(Sung Ro Chung),황윤영(Youn Yeung Hwang),문형(Hyung Moon),이유경(Yoo Kyoug Lee) 대한산부인과학회 2002 Obstetrics & Gynecology Science Vol.45 No.3
Objective: Recently, enormous amount of the studies about trial of labor after cesarean section has been reported to decrease the rate of cesarean section. This study focused on analyzing multiple variables and results to acknowledge the safety and complications of VBAC (vaginal birth after cesarean section). Methods & materials: This study was performed based on 97 pregnant women who were tried vaginal delivery after cesarean section at Hanyang University Hospital from January 1990 to December 1999.The age of mother, gestational age, estimated fetal body weight by ultrasonography, neonatal body weight, cervical dilatation, cervical effacement, Bishop score, the number of previous vaginal delivery, complications of mother, and complications of fetus were analyzed between successful group (82 patients)and failure group (15patients)with trial of labor. Student T-test and Chi-square test were used for statistical analysis. Results: In the 97 cases with trial of labor after cesarean, the success rate was 84.5%and failure rate was 15.5%. The estimated fetal body weight by ultrasonography, cervical dilatation and effacement, Bishop score, Apgar score had notable differences between successful group and failure group, while the other factors had not. There was no maternal death or uterine rupture in the cases of trial of labor. Conclusion: Trial of labor after cesarean section is relatively safe method of delivery if it is performed under strict indication. It could be suggested that VBAC has relatively little complication in both mother and fetus. The studies with large populations and performed by multi-centers will be needed for the evaluating safety of VBAC and developing safe protocols to decrease the risk of complications.
난소암 세포주와 cisplatin 내성주에서의 MDR 관련 유전자의 발현에 관한 연구
문영진(Young Jin Moon),황윤영(Youn Yeung Hwang),이재규(Jai Kyu Lee),나영정(Young Jeong Na),이영미(Young Mi Lee),장성렬(Sung Yeoul Chang),조삼현(Sam Hyun Cho),김경태(Kyung Tai Kim) 대한산부인과학회 2001 Obstetrics & Gynecology Science Vol.44 No.9
Objective : Expressions of P-glycoprotein, the multidrug resistance-associated protein (MRP) and the lung resistance protein (LRP) with the MDR phenotype widely divergent in human cancer cell lines. This study focused on the altered gene expression related drug transport. Methods : To examine correlations between MDR-associated genes and PKC isozyme with cisplatin resistance on the level of the mRNA expression, we analyzed MDR-associated gene (LRP, MDR1/P-gp and MRP) expression and PKC isozyme, topoisomerase II alpha and beta in cisplatin-sensitive ovarian cancer cell line A2780 and cisplatin - resistant cell line A2780cp using cDNA-PCR approach. Results : LRP mRNA levels were significantly increased in A2780cp compared to the drug sensitive variant. In contrast, MRP mRNA levels were not significantly correlated with drug sensitivity. A modest increase in PKCη and MDR1/P-gp mRNA expression activity was also observed in ovarian cancer A2780cp cell lines that were resistant to CDDP. The level of topoisomerase II alpha and beta were not affected. Conclusion : These results showed that MDR1/P-gp expression may be an important determinant of the MDR phenotype in cell lines intrinsically resistant to cancer chemotherapeutic agents and a multifactorial emergence of MDR phenotype of tumor with a possible involvement of the PKC isozymes may be associated with CDDP resistant ovarian cancer cell line.
암세포 Bcl-2 family 유전자 군의 DNA 메틸화 연구
강영섭 ( Young Suep Kang ),이선영 ( Sun Young Lee ),정상근 ( Sang Gun Jung ),한지유 ( Ji You Han ),고정재 ( Jeong Jae Ko ),배지현 ( Jee Hyeon Bae ),나영정 ( Young Junh Na ),이찬 ( Chan Lee ),목정은 ( Jung Un Mock ),김승조 ( Sung 대한산부인과학회 2007 Obstetrics & Gynecology Science Vol.50 No.7
Objective: Promoter methylation of Bcl-2 family genes in cancer cells were studied to verify possible correlation between DNA methylation pattern of Bcl-2 family members and cancer. Methods: The genomic DNAs were extracted from different cancer cell lines, HeLa, CaSki and K562, and ovarian cancer tissue from patients. The cytosine residues were converted to uracil by sodium bisulfite treatment. MSP (methylation specific PCR) was performed to determine the methylation status of Bcl-2, Mcl-1, Noxa, and Harakiri promoters. Using primers that distinguish methylated DNA from unmethylated DNA after bisulfite modification of DNA, MSP was conducted to observe the methylation pattern of Bcl-2 family genes in different cancer cells. Results: The promoter regions of Bcl-2 family genes including Mcl-1, Bcl-2, and Noxa were not methylated in cancer cells, whereas the proapoptotic Bcl-2 family gene Harakiri was detected as methylated in the cancer cell lines and hypomethylated in the ovarian cancer tissue. Conclusion: The present study demonstrated the differential methylation profiles of Bcl-2 family genes in cancerous cells, which suggests a possible connection between the methylation pattern of some of Bcl-2 family genes and ovarian cancer.
프로게스테론과 프로게스틴이 인간 제대 정맥 내피세포의 세포 고사에 미치는 영향
류기영(Ki Young Ryu),박영준(Young Joon Park),권희선(Hee Sun Kwon),나영정(Young Jeong Na),조수현(Soo Hyun Cho),조삼현(Sam Hyun Cho),황윤영(Youn Yeung Hwang) 대한산부인과학회 2002 Obstetrics & Gynecology Science Vol.45 No.10
Objective : The addition of progesterone/progestin is mandatory in women with intact uterus for postmenopausal hormone replacement therapy. However, debate is continuing on whether there is an impact of progesterone/progestin on the hormone replacement therapy for cardiac protection. The aim of this study was to investigate the effect of progesterone/progestin and combination with estrogen on the apoptosis of vascular endothelial cells, which has been demonstrated to be an initial step in the development of atherosclerosis. Material and methods : Human Umbilical Vein Endothelial Cells (HUVEC) were cultured. HUVEC apoptosis was induced by Tumor Necrosis Factor-α (TNF-α) (50 ng/ml). 10-7M of estradiol (E2), progesterone (P4), medroxyprogesterone acetate (MPA) and norethindrone acetate (NETA) were added in to the culture media. The percentage of apoptotic HUVEC were measured by 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay and Fluorescence Activated Cell Sorting (FACS) analysis. Results : MTT assay demonstrated a significant decrease in percent of survival cells after 24 hours of TNF-α exposure and a reversal of the effect of TNF-α with E2 treatment. P4, MPA and NETA treatment also reversed the effect of TNF-α. The protective effect of E2 and P4 were not different. Compared to the E2 treatment, the percent of survival cell were decreased when P4, MPA and NETA were added to E2 treatment, respectively. Similarly, FACS analysis revealed 44.0±2.6% apoptosis after 24 hours of TNF-α exposure. Treatment with E2 resulted a significant decrease (28.4±2.9%, p<0.05) in apoptosis. P4 (33.6%±2.6%, p<0.05), MPA (35.7±1.3%, p<0.05), NETA (34.0±3.3%, p<0.05) treatment also showed a reduction of cell death. The percent of apoptotic cells between E2 and MPA treatment was significantly different. The addition of P4 (36.0±2.5%), MPA (36.3±1.9%) and NETA (37.0±2.0%) to E2 treatment significantly increased the percent of apoptotic cells compared to those of E2 treatment. Conclusion : These results suggested that not only estradiol, but also progesterone, MPA and NETA inhibited HUVEC apoptosis. But the effect of estrogen on the inhibition of HUVEC apoptosis was attenuated in combination treatment of estrogen and progesterone/progestin.
신지은 ( Ji Eun Shin ),나영정 ( Young Jeong Na ),이찬 ( Chan Lee ),정상근 ( Sang Guen Jung ),박혜리 ( Hea Ree Park ),김태헌 ( Tae Heon Kim ),황윤영 ( Yeun Young Hwang ) 대한산부인과학회 2008 Obstetrics & Gynecology Science Vol.51 No.11
Endometriosis is a common disease in women of reproductive age, intestinal involvement has been estimated to occur in 3% to 37% of women with endometriosis, in rectosigmoid colon, appendix, ileum and cecum, in order of decreasing frequency. On the other hand, endometriosis of the small bowel, especially symptomatic small bowel involvement, is very unusual. Endometriosis is a rare cause of intestinal obstruction, and preoperative diagnosis is very difficult. It should be considered in the differential diagnosis of women of reproductive age who present with symptoms of obstruction. The definitive treatment includes resection of the involved segment with primary anastomosis. We report a 34-year-old woman following up infertility and ovarian endometrioma. She had nausea, vomiting and low abdominal pain who was operated on acute intestinal obstruction. Pathologic finding was endometriosis involving the ileum, cecum, appendix We present the case with a brief review of literature.
이정열 ( Jung Ryul Lee ),차진영 ( Jin Young Cha ),조헌영 ( Hun Young Cho ),이유경 ( Yoo Kyung Lee ),박민수 ( Min Soo Park ),이유석 ( Yoo Seok Lee ),나영정 ( Young Jeong Na ),조수현 ( Soo Hyun Cho ),조삼현 ( Sam Hyun Cho ),정성로 ( 대한산부인과학회 2002 Obstetrics & Gynecology Science Vol.45 No.12
Objective : To evaluate the various effects of hormone replacement therapy (HRT) on bone mineral density (BMD) for 4 years in postmenopausal women and to compare the characteristics of non-responders to HRT. Methods : A total of 100 postmenopausal women h
자궁근종이 있는 한국여성에서 자기공명영상 유도하 고집적 초음파수술: 초기 임상경험
윤상욱 ( Sang Wook Yoon ),김경아 ( Kyoung Ah Kim ),황윤영 ( Youn Young Hwang ),이찬 ( Chan Lee ),차선희 ( Sun Hee Cha ),이선영 ( Sun Young Lee ),김용민 ( Yong Min Kim ),나영정 ( Young Jeong Na ),정상근 ( Sang Geun Jung ),김승조 ( 대한산부인과학회 2008 Obstetrics & Gynecology Science Vol.51 No.9
Objective: The purpose of this report is to review the safety and short-term efficacy of non-invasive magnetic resonance imaging-guided focused ultrasound surgery (MRgFUS) on uterine myomas in Korean women. Methods: A total of 29 outpatient Korean women, whose mean age was 39.1±5.8 years, were treated using the MRgFUS system for their symptomatic uterine myomas. Patients` symptoms were recorded using a validated symptom-specific questionnaire on treatment day, and at follow-up visits, 3 and 6 months post treatment. Data on adverse events was recorded on each follow up period. Results: Symptom improvement was experienced by 83% of the patients at the three months follow-up, and 90% of the patients reported on improved quality of life by the six months follow-up. There were no serious adverse events during the treatments or the follow-up period. Conclusion: MRgFUS appears to be a safe and effective treatment for symptoms relief of uterine fibroids. Additional reports on longer follow up should verify long-term durability.
임신성 융모성 질환에서 혈청 β-hCG 의 소실기간과 양상에 관한 연구
강정권(Jung Kweon Kang),구인상(In Sang Ku),차진영(Jin Young Cha),김현희(Hyun Hee Kim),김영재(Young Jae Kim),이유석(Yoo Seock Ree),배은경(Eun Kyung Bae),나영정(Young Jeong Na),김경태(Kyung Tai Kim),조수현(Soo Hyun Cho),조삼현(Sam Hyun 대한산부인과학회 2002 Obstetrics & Gynecology Science Vol.45 No.4
Objectives : It is now conventional practice to use human chorionic gonadotropin (hCG) as the marker of tumor activity in gestational trophoblastic disease (GTD). The interpretation of serial serum β-hCG regression patterns is important in monitoring the course of the disease. The purpose of this study was to establish a regression time and pattern of the serum β-hCG in which GTD is divided into hydatidiform mole and malignant trophoblastic disease. Materials & Methods : During the period from January 1990 through December 2000, 46 patients with GTD were histopathologically diagnosed and treated at the department of Obstetrics and Gynecology in Hanyang University Hospital. For the purpose of analysis and comparison, patients were divided into 19 cases of hydatidiform mole and 27 cases of malignant trophoblastic disease which was subdivided into nonmetastatic (17) and metastatic (10). Patients were followed clinically and by weekly estimations of quantitative serum β-hCG until negative (<3 mIU/ml). After three consecutive negative β-hCG, serum β-hCG were drawn monthly in all patients for one year. The level of serum β-hCG was detected by two-site sandwich immunoassay (Chiron Diagnostics Automated Chemiluminescence System 180). The obtained data were analyzed using t test and ANOVA test by SPSS. Results : The incidence of the GTD compared with delivery was one per 182.7 deliveries. The mean value of serum β-hCG regression time in hydatidiform mole was 12.8±1.1 (SEM) weeks (7.0-26.0 weeks) and 17.9±1.4 (SEM) weeks (8.0-34.0 weeks) in malignant trophoblastic disease. The regression time was significantly shorter in hydatidiform mole than that of malignant trophoblastic disease (P<0.01). The differences of mean value of serum β-hCG regression time between the groups with nonmetastatic (18.0 weeks) and metastatic (17.8 weeks) were not statistically significant(P =0.946). The mean values of serum β-hCG in both hydatidiform mole and malignant trophoblastic disease declined following a log-normal distribution. Conclusions : The regression pattern of serum β-hCG in present study was similar to that of which in Western and also similar to that of which in Korea in 1980s. The present study supports the continued use of individual patients serum β-hCG regression curve to make treatment decision and to recognize malignant trophoblastic disease promptly.
상피성 난소암에서 Wnt 1과 β-catenin의 발현에 관한 연구
임경란 ( Kyoung Ran Yim ),이찬 ( Chan Lee ),김용민 ( Yong Min Kim ),김광일 ( Kwang Il Kim ),김승조 ( Seung Jo Kim ),황윤영 ( Youn Yeung Hwang ),이선영 ( Seon Yeong Lee ),나영정 ( Young Jeong Na ),정상근 ( Sang Geun Jeong ),오예은 대한산부인과학회 2008 Obstetrics & Gynecology Science Vol.51 No.9
Objective: We were trying to identify the expression of Wnt 1 and β-catenin in normal ovarian epithelium and epithelial ovarian tumor. Methods: We used archival formalin-fixed and paraffin-embedded tissues from Comprehensive Gynecologic Cancer Center and the Department of Pathology at Bundang CHA Hospital from 2000 to 2005. Immunohistochemical staining for Wnt 1 and β-catenin was performed on the ovarian epithelial tissues. Statistical analyses were performed with SPSS 10.1 for Windows and significance was defined as P<0.05. Results: Of 114 cases, the cases were composed of 54 carcinomas, 40 borderline tumors, 12 benign tumors and 8 normal control ovarian tissues. Abnormal nucleocytoplasmic expression of β-catenin was found in 4 endometrioid carcinomas. The nuclear expression of β-catenin was found especially in the components of the endometrioid carcinoma (28.6%, P<0.05). Wnt 1 was overexpressed in all 9 clear cell carcinomas, but not frequent in the other types of malignant tumors (P<0.05). We found a statistically significant correlation between β-catenin nuclear localization and endometrioid carcinomas. And we found a significant correlation between Wnt 1 expression and clear cell carcinomas. Conclusion: It does not seem that Wnt 1 over expression directly provoke the nuclear localization of β-catenin. But, deregulation of β-catenin and Wnt 1 may play a role in the pathogenesis of ovarian epithelial carcinogenesis of endometriod carcinoma and clear cell carcinoma. Evaluating this avenue of regulation of β-catenin and Wnt protein in ovarian epithelial carcinoma may provide a new direction for early diagnosis and treatment in ovarian epithelial carcinoma and provide opportunities for making a certain biomarkers.
자궁내막암에 있어 수술 후 보조 방사선치료법과 수술 후 복합항암화학치료법의 임상 비교 연구
최민철 ( Min Chul Choi ),박지현 ( Ji Hyeon Park ),김수현 ( Su Hyun Kim ),전경훈 ( Kyung Hun Jun ),정상근 ( Sang Geun Jung ),나영정 ( Young Jeong Na ),이선영 ( Sun Young Lee ),이찬 ( Chan Lee ),황윤영 ( Yeun Young Hwang ),김승조 ( 대한산부인과학회 2008 Obstetrics & Gynecology Science Vol.51 No.11
Objective: This study was performed to compare postoperative adjuvant paclitaxel and platinum (TC) chemotherapy and radiation therapy in women with uterine endometrial carcinoma. Methods: Total one hundred five patients were entered into this trial. Non-endometrioid histologic subtypes such as serous, clear cell and small cell types were excluded from the study because they have different biological potentials. Of 58 assessable patients, who were needed adjuvant treatment according to surgico-pathologic reports, after surgery, 34 were received TC chemotherapy and 24 were received radiation therapy. Chemotherapy consisted of paclitaxel 175 mg/m2 and carboplatin AUC 5 (or cisplatin 50 mg/m2) every 3 weeks for 3 or 6 cycles. Irradiation dosage was 4,500~5,040 cGy in 28 fractions. Results: In 58 evaluated patients, median follow-up time was 40.3 months (range 7~64 months). The 5-year overall survival and 5-year disease-free survival were 91.3% and 91.0% in 34 patients treated with TC chemotherapy, and 91.4% and 82.8% in 24 cases who treated with radiation therapy, however, there were no significant difference (P=0.646, P=0.129). The most common adverse effect of TC chemotherapy was hematologic toxicity, which was manageable conservatively. The serious gastrointestinal complication of radiotherapy was noted in 5 patients (20.8%), three of these patients were received another bowel surgery, such as ileo-cecal bypass, however, symptoms were persisted after surgery. Conclusions: These data suggest that postoperative adjuvant TC chemotherapy is a promising treatment which could be substituted for radiation therapy, with major activity and a acceptable toxicity profile for the treatment of uterine endometrial carcinoma.